Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3529]

World first as viral immunotherapy for skin cancer shows patient benefit in phase III trial

World first as viral immunotherapy for skin cancer shows patient benefit in phase III trial

ASCO 2015: Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

ASCO 2015: Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

Stabilised mutant p53 is an important determinant of tumour survival and a valid drug target

Stabilised mutant p53 is an important determinant of tumour survival and a valid drug target

Circulating tumour DNA in blood predicts recurrence of common lymphoma type

Circulating tumour DNA in blood predicts recurrence of common lymphoma type

Insights into a signalling process that enhances the effectiveness of cancer immunotherapy

Insights into a signalling process that enhances the effectiveness of cancer immunotherapy

Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

Researchers quantify the proportion of different genetic mutations contained within individual bowel cancers

Researchers quantify the proportion of different genetic mutations contained within individual bowel cancers

IMPAKT 2015: Constitutively activated STAT3 may be a predictive marker for resistance to trastuzumab in patients with HER2 positive breast cancer

IMPAKT 2015: Constitutively activated STAT3 may be a predictive marker for resistance to trastuzumab in patients...

Study finds metabolic link between bacterial ‘biofilms’ and colon cancer

Study finds metabolic link between bacterial ‘biofilms’ and colon cancer

Cell movement dynamics sheds light on cancer therapy

Cell movement dynamics sheds light on cancer therapy

More from ecancer